• If you are wondering whether Guardant Health at around US$149 per share is still offering value after a big run, the key is to separate price excitement from underlying worth.
• The stock has delivered returns of 13.2% over the past week, 15.1% over the past month, 46.7% year to date, 193.4% over 1 year, 316.8% over 3 years and 20.1% over 5 years, which naturally raises questions about how much future upside or downside is already priced in.
• Recent headlines around Guardant Health have kept the stock in focus, with investors paying close attention to how its products and partnerships position it within healthcare. These developments provide important context when assessing whether the current share price around US$149 simply reflects sentiment or aligns with underlying fundamentals.
• Despite the strong share price history, Guardant Health currently has a value score of 1/6. The next sections will break down what different valuation methods say about the stock and then finish with a broader framework that can help you judge valuation more effectively over time.

Guardant Health scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Guardant Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what Guardant Health stock might be worth today by projecting the company’s future cash flows and discounting them back to a single present value figure.

For Guardant Health, the latest twelve month free cash flow (FCF) shows an outflow of $232.49 million. Analysts and model estimates project FCF to shift over time, with a forecast of $386.6 million in 2030. The 2 Stage Free Cash Flow to Equity model uses a mix of analyst forecasts for the earlier years and extrapolated figures by Simply Wall St for the later years to build a 10 year cash flow path in dollars, and then discounts each year back to today.

Adding those discounted cash flows together and adjusting for equity results in an estimated intrinsic value of about $159.10 per share for Guardant Health. Against the current share price around $149, the DCF output points to the stock trading at roughly a 6.2% discount, which is a relatively small gap.

Result: ABOUT RIGHT

Guardant Health is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Approach 2: Guardant Health Price vs Sales

For companies like Guardant Health that are still working toward consistent profitability, the P/S ratio is often more useful than P/E or P/B. It compares what the market is paying for each dollar of revenue, which can be easier to interpret when earnings and book value are not yet steady.

In general, higher growth expectations and lower perceived risk tend to support a higher “normal” valuation multiple, while slower growth and higher risk usually point to a lower one. Guardant Health currently trades on a P/S ratio of 18.32x. This sits well above the Healthcare industry average P/S of 1.32x and the peer average of 1.42x, which on simple comparison suggests a rich valuation.

Simply Wall St’s Fair Ratio framework goes a step further. It estimates what a more tailored P/S multiple might look like by factoring in elements such as earnings growth, profit margins, industry, market cap and specific risks. For Guardant Health, the Fair Ratio is 7.86x, which is meaningfully below the current P/S of 18.32x, indicating the stock is pricing in stronger conditions than this model supports.

Result: OVERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Guardant Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives take Guardant Health beyond static ratios by letting you link a clear story about the business to a set of financial assumptions. These then flow through to a fair value that you can easily compare with the current share price on Simply Wall St’s Community page, where millions of investors share their views and where each Narrative automatically refreshes when new earnings, guidance or news arrive.

In practice, you choose the story you believe, translate it into revenue, earnings and margin paths, and the platform turns that into a fair value that helps you consider whether Guardant Health appears expensive or cheap relative to its current price, instead of relying only on broad multiples.

For Guardant Health, one Narrative might look closer to the bullish cohort, using the higher revenue growth and earnings assumptions that support a fair value around US$140. Another might lean toward the bearish cohort, using the more cautious expectations that anchor fair value closer to US$82. Seeing both side by side can make it easier to consider which story, if either, aligns with your own expectations and risk tolerance.

Do you think there's more to the story for Guardant Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.